CDK4 and neoplasm: In the tumor cell line with acquired resistance to palbociclib, it was demonstrated that resistance to CDK4/6 inhibitors was mediated through Rb1 loss, and restoration of Rb1 expression rendered tumor cells sensitivity to the CDK4/6 inhibitor (15).